Oct 22, 2019
SANTA MONICA, CA / ACCESSWIRE / October 22, 2019 / BioVie Inc. (OTCQB:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has submitted for assessment by the U.S. Food and Drug Administration ("FDA") the Phase 2b...
Apr 30, 2019
LOS ANGELES, April 30, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced top-line results for its Phase 2a clinical trial of BIV201 (continuous infusion terlipressin) ...
Apr 24, 2019
LOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced that Mr. Terren Peizer, the Company’s Chairman and CEO, is scheduled to participate in the ThinkEq...